Elucid

Elucid is a medical technology company that focuses on artificial intelligence software for diagnosing and treating cardiovascular disease. Their flagship product, PlaqueIQ™, is the first FDA-cleared software that uses AI to analyze arterial plaque from coronary computed tomography angiography (CTA) images. This innovative technology helps physicians visualize and assess different types of plaque, including those that are high-risk and not visible to the human eye. The software provides actionable, lesion-specific information that aids cardiologists in determining the best treatment options for patients based on their unique plaque composition. Elucid's solutions are designed to integrate seamlessly into clinical workflows, enhancing risk assessment and personalized care for cardiovascular patients. The company primarily serves clinical cardiologists and large health systems, with recognition from insurance payers like United Healthcare, which has updated its guidelines to include coverage for their technology. Elucid is experiencing significant growth and is expanding its commercial presence following a successful funding round.

• Employees 130
• Founded 2013
• Annual Revenue $50000000
• Total Funding $134696200